News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arcutis Biotherapeutics, Inc.
< Previous
1
2
Next >
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
January 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
January 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
December 15, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
November 29, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
November 03, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Report Third Quarter 2023 Financial Results
October 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
October 20, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Pricing of $100 Million Public Offering
October 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Proposed Public Offering
October 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
October 13, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
October 06, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
September 27, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
September 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
September 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
September 12, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
September 07, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Present at Upcoming Investor Conference
September 05, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
August 31, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
August 29, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Appoints Interim Chief Financial Officer (CFO)
August 18, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
August 10, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Report Second Quarter Financial Results
July 24, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
July 17, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Present at Upcoming Investor Conference
June 06, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
May 02, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
April 28, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Report First Quarter Financial Results
April 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
April 18, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.